Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00265161
Other study ID # 4180905
Secondary ID
Status Completed
Phase N/A
First received December 12, 2005
Last updated May 31, 2007
Start date December 2005
Est. completion date March 2007

Study information

Verified date August 2006
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Observational

Clinical Trial Summary

The study will be held in the winter of 2005-2007. The aim is to assess the effectiveness of the influenza vaccine in health care workers (HCW).


Description:

The study will be held in the winter of 2005-2006. Groups of vaccinated HCW and not vaccinated HCW will be followed for symptoms suggestive of influenza. For each event a quick through test for influenza A or B will be done and if positive will be confirmed by viral study. Data regarding days of illness, absence from work, therapy etc., will be collected. Effectiveness will be calculated as well as cost/effectiveness of vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Previously healthy health care worker vaccinated or not

Exclusion Criteria:

- Immunocompromised state

Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Pediatric Dpt A', HaEmek Medical Center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Completed NCT03246100 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado N/A
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT02761551 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT03735147 - Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children Phase 4
Completed NCT02831608 - Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis Phase 4
Completed NCT02560909 - Adjuvanted Influenza Vaccine in Stem Cell Transplant Phase 4
Withdrawn NCT01623232 - MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly Phase 1/Phase 2
Completed NCT00961337 - Evaluation of a School-based Influenza Vaccination Program Phase 4
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Completed NCT00222638 - Influenza Vaccination and Oral Anticoagulant Therapy Phase 4
Active, not recruiting NCT03734237 - A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD Phase 4
Completed NCT01013675 - Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly Phase 2
Completed NCT00306995 - Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population Phase 2
Completed NCT01310413 - Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Phase 3
Completed NCT00449670 - Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults Phase 3
Completed NCT01788228 - Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Phase 3
Completed NCT00296270 - Memory for Flu Facts and Myths and Effects on Vaccine Intentions N/A
Recruiting NCT05521763 - Influenza Vaccine Uptake Among Healthcare Workers N/A
Completed NCT00718120 - Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years Phase 3